Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

appointment Lucie Larguier et Christelle Schwoerer

Published 27 March 2024
Categorized as 2024, Press release

Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

2023 financial results and business update

Published 27 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene Announces Upcoming Investor Meetings

upcoming investor meetings

Published 18 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

TG4050 AACR 2024

Published 6 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

Transgene Nec and BostonGene expand collaboration

Published 5 March 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

financial calendar 2024

Published 22 January 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene Announces Financial Calendar for 2024

financial calendar 2024

Published 22 January 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

Transgene and NEC extend their collaboration

Published 8 January 2024
Categorized as 2024, dates, Myvac, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

upcoming investor meetings

Published 21 December 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

nomination A Dubarry

Published 5 December 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Posts pagination

Newer posts Page 1 … Page 8 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu